Yposkesi is France’s most important bioproduction sovereignty asset in gene therapy — a Contract Development and Manufacturing Organization (CDMO) that produces the viral vectors that gene therapies require to deliver genetic material into patient cells. Without reliable viral vector manufacturing capacity, gene therapy programs — some of the most promising treatments for previously incurable genetic diseases — cannot progress from clinical trials to commercial treatments. Yposkesi provides that manufacturing capacity in France, supporting French pharmaceutical sovereignty in a technology sector that is strategically critical.
Founded in 2016 in Évry-Courcouronnes, south of Paris — in the Genopole biotechnology cluster, France’s largest life science research and industry campus — Yposkesi operates state-of-the-art GMP (Good Manufacturing Practice) facilities for lentiviral vector and AAV (adeno-associated virus) vector production. These are the primary delivery vehicles for gene therapies targeting conditions including hemophilia, inherited blindness, spinal muscular atrophy, and various cancers.
France 2030 Funding and Projects
Yposkesi is a direct beneficiary of France 2030’s bioproduction sovereignty strategy — one of the plan’s most explicit objectives is to establish French manufacturing capability for advanced biotherapies, reducing dependence on US and foreign CDMOs for critical medical supply chains.
Lentiviral vector manufacturing is Yposkesi’s founding capability. Lentiviral vectors (derived from HIV, engineered to be non-replicating and non-pathogenic) are used to permanently insert therapeutic genes into T cells or hematopoietic stem cells in CAR-T immunotherapy and ex-vivo gene therapy. The manufacturing process involves complex upstream cell culture (producer cells generating viral particles), downstream purification (chromatography, filtration to concentrate and purify the virus), and rigorous quality control testing. Yposkesi produces clinical and commercial-grade lentiviral vectors for external gene therapy developer clients. France 2030 co-funded capacity expansion at the Évry facility specifically for lentiviral vector manufacturing, directly addressing France’s identified gap in domestic CAR-T therapy manufacturing.
AAV vector manufacturing covers adeno-associated viruses — the preferred delivery vehicle for in-vivo gene therapies targeting liver, muscle, eye, and central nervous system. AAV therapies include Novartis’s Zolgensma (the most expensive drug in history at $2.1 million per dose, treating spinal muscular atrophy) and several hemophilia gene therapies approaching approval. AAV manufacturing is technically demanding and capacity-constrained globally — there are fewer than 20 commercial-scale AAV manufacturing facilities worldwide, and several of those are in the US. Yposkesi’s French AAV capacity is therefore a strategic European asset. France 2030 explicitly targets AAV manufacturing as a bioproduction sovereignty gap requiring domestic capability.
Plasmid DNA production is the upstream input required for both lentiviral and AAV vector manufacturing. Plasmids (circular DNA molecules) serve as the genetic template that cells use to produce viral vector particles; they are also used directly in DNA vaccination and other genetic medicine applications. Yposkesi has invested in plasmid DNA manufacturing capacity at Évry, creating a vertically integrated supply chain from genetic template through finished vector product that reduces supply chain vulnerability and maintains quality control throughout.
Genopole campus integration provides Yposkesi with unique access to the French gene therapy research ecosystem. Located within Genopole — which houses AFM-Téléthon’s Généthon gene therapy research institute, INSERM research units, and dozens of gene therapy startups — Yposkesi has proximate relationships with the academic and clinical researchers whose programs become its manufacturing clients. This campus co-location mirrors the model France 2030 is creating across multiple sectors: research and manufacturing in close physical proximity.
Strategic Position
Yposkesi’s competitive position in European gene therapy CDMO services is genuinely strong. The global landscape is dominated by US CDMOs (Lonza, WuXi Biologics, Catalent, Thermo Fisher), but European regulatory requirements and French sovereignty preferences create a home market advantage. For French academic institutions (AP-HP hospitals, INSERM units), French pharmaceutical companies (Sanofi, Ipsen), and European gene therapy companies seeking European manufacturing provenance for EU regulatory submissions, Yposkesi is the preferred partner.
The company’s AFM-Téléthon founding relationship (AFM-Téléthon, the French muscular dystrophy charity, was a founding investor) provides a unique institutional connection — and ensures Yposkesi’s priorities align with patient access as well as commercial optimization.
France 2030’s stated objective of making France a global bioproduction hub for cell and gene therapy directly supports Yposkesi’s commercial strategy. If France succeeds in establishing itself as Europe’s center for gene therapy manufacturing (as it ambitions), Yposkesi benefits proportionally.
Key Technology and Innovation
Yposkesi’s most technically differentiated capabilities are in its purification processes — the downstream steps that remove impurities from viral vector preparations to achieve the purity required for clinical use. Gene therapy vectors are far more complex to purify than conventional biologics; the purification process must remove empty viral particles (no therapeutic gene), aggregated particles, and process-related impurities while maintaining the potency of the filled particles. Yposkesi’s proprietary purification processes, developed over years of clinical manufacturing experience, achieve high yields and purities that are difficult for competitors to replicate quickly.
The company’s analytical capabilities — the battery of tests required to characterize a gene therapy vector preparation — are equally important. FDA and EMA require comprehensive characterization of vector potency, identity, purity, and safety before any clinical or commercial lot can be released, and Yposkesi has invested in the analytical infrastructure to perform these tests internally.
Leadership
CEO Cécile Chartier has led Yposkesi through its founding and growth phases, managing the complex balance between clinical-stage manufacturing (where customer specifications change frequently) and commercial manufacturing (where consistency and scale are paramount). Her background in biopharmaceutical operations provides the process engineering and quality management expertise essential for a GMP facility serving regulated pharmaceutical clients.
Competitive Landscape
Yposkesi competes primarily with US-headquartered CDMOs for European gene therapy manufacturing contracts. Within Europe, Cobra Biologics (UK, acquired by Catalent), ElevateBio’s BaseCamp Manufacturing (US, but Europe-expanding), and Charles River Laboratories are relevant competitors. Yposkesi’s French identity, Genopole ecosystem integration, and France 2030 bioproduction sovereignty positioning create home market advantages that international CDMOs cannot easily replicate.
Investor Perspective
Yposkesi is not publicly listed. The company has received Bpifrance investment alongside AFM-Téléthon’s founding stake and potentially other institutional investors. France 2030 bioproduction grants and loans reduce the capital cost of facility expansion, improving the economics of a business with high capital requirements (cleanroom construction, specialized equipment) and lumpy revenue from clinical-stage clients whose programs face binary regulatory outcomes.
The long-term investment thesis is compelling: global gene therapy pipeline is growing faster than manufacturing capacity, European bioproduction sovereignty is a stated priority of both France 2030 and EU health policy, and Yposkesi’s established capabilities and Genopole location provide structural advantages that new entrants cannot quickly replicate.
Related Companies
- Sanofi — French pharmaceutical major with gene therapy programs that could use Yposkesi’s manufacturing
- DNA Script — synthetic DNA synthesis company upstream in the same genetic medicine ecosystem
- bioMérieux — French health technology company in the broader France 2030 health ecosystem
- Valneva — fellow French bioproduction company under France 2030’s health sovereignty agenda
- Bpifrance — co-investor and France 2030 bioproduction program operator